The Role of Omalizumab in the Treatment of Severe Allergic Asthma

Affiliations

Kenneth R Chapman: Department of Medicine, Division of Respiratory Medicine, University of Toronto, Toronto, Ontario, Canada
Andre Cartier: Department of Medicine, Division of Respiratory Medicine, University of Montreal, Montreal, Canada
Jacques Hébert: Allergy and Clinical Immunology, Centre hospitalier universitaire de Québec and Centre de recherché appliqué en allergie de Québec, Laval University, Laval, Quebec, Canada
R Andrew McIvor: Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada
R Robert Schellenberg: Department of Medicine, Division of Allergy and Immunology, University of British Columbia, Vancouver, British Columbia, Canada

Abstract

BACKGROUND: A novel anti-immunoglobulin E (anti-IgE) therapy for asthma, omalizumab, has been approved for use in Canada.

ISSN: 1198-2241 (Print); 1916-7245 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://onlinelibrary.wiley.com/journal/7503